Clinical trials: Female Breast Neoplasms
Breast Cancer
Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
This is a pivotal phase II, multicenter, open-label trial, designed to compare the efficacy of exemestane versus anastrozole as a first line treatment for advanced breast cancer.
- Trial name
- NCT00128843
- Testing
- Exemestane, Anastrozole
- Where
- 13 sites in Spain
- Volunteers
- 103 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer Prevention, Mammographic Density
RANKL Inhibition and Breast Tissue Biomarkers
A robust knowledge of how to reduce breast density could play a key role in breast cancer prevention in premenopausal women, but viable preventative targets to reduce breast density-associated breast cancer risk are yet to be…
- Trial name
- NCT03629717
- Testing
- Ultrasound-guided core needle biopsy, Denosumab, Blood draw
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent
Breast Cancer
Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer
The purpose of the study is to assess the benefit of panobinostat monotherapy given either orally or i.v. to women with HER2-positive locally recurrent or metastatic breast cancer
- Trial name
- NCT00777335
- Testing
- Panobinostat - LBH589
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Translational Research in Oncology
Breast Cancer
Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer
Adjuvant chemotherapy with the protocol 3 cure of 5-FU + Epirubicine + Cyclophosphamide (FEC100) and 3 cure of Taxotere is a standard treatment in the management of patients with breast cancer and in adjuvant situation.
- Trial name
- PREDIGOSTEO (NCT02840890)
- Testing
- osteopathic technique
- Where
- France
- Volunteers
- 94 people
- Sponsor
- Centre Georges Francois Leclerc
Breast Cancer Survivor
A Mindfulness-Based Self-Compassion Program
The purpose of this study is a pre-test-post-test, randomized controlled experimental study with a control group, planned to examine the effect of the mindfulness-based self-compassion program applied on women with breast cancer…
- Trial name
- NCT06846060
- Testing
- Mindfulness-Based Self-Compassion Program
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Nevsehir Haci Bektas Veli University
Breast Cancer, Hot Flashes
Black Cohosh in Treating Hot Flashes in Women Who Have or Who Are At Risk of Developing Breast Cancer
RATIONALE: The herbal supplement black cohosh may be effective in relieving hot flashes in women. PURPOSE: Randomized phase III trial to determine the effectiveness of black cohosh in relieving hot flashes in women who have…
- Trial name
- NCT00060320
- Testing
- black cohosh
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Ovarian Neoplasms, Breast Neoplasms
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01095848
- Testing
- DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
All early breast cancer patients are offered adjuvant breast radiation therapy (RT) after breast conserving surgery for an early breast cancer.
- Conditions
- Local Neoplasm Recurrence, Distantly Metastatic Malignant Neoplasm, Death, Fibrosis Breast
- Trial name
- NCT03646955
- Testing
- No partial breast irradiation
- Where
- 17 sites in Chile, Denmark and 2 more
- Volunteers
- 926 people
- Sponsor
- Danish Breast Cancer Cooperative Group
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Colorectal Cancer Metastatic, Triple Negative Breast Cancer
A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
This study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and…
- Conditions
- Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03775850
- Testing
- EDP1503, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Evelo Biosciences, Inc.
HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells
DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Several studies have indicated that determining prevalence and number of circulating tumor cells (CTCs) at various time points during treatment may be an effective tool for assessing treatment efficacy in metastatic breast cancer…
- Conditions
- HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients
- Trial name
- NCT02035813
- Testing
- Ribociclib, Eribulin
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Prof. Wolfgang Janni
Breast Cancer
Interventional Program Educates, Identifies + Overcomes Barriers to Complete Screening Mammography
The purpose of this study is to identify interventions that are designed to better serve women who are homeless, with a specific focus on increasing screening rates and decreasing late stage breast cancer diagnosis among this…
- Trial name
- NCT04348123
- Testing
- Survey, Education Session
- Where
- United States
- Volunteers
- 203 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Cancer
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives…
- Trial name
- CMIST (NCT05625659)
- Testing
- Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 2,032 people, healthy volunteers welcome
- Sponsor
- American College of Radiology
Breast Cancer
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103233
- Testing
- trastuzumab, vinorelbine tartrate
- Sponsor
- SWOG Cancer Research Network
Breast Cancer
Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers
The purpose of this study is to determine whether high dose of radiation therapy (RT) are effective over standard 6-week radiation treatment in patients with breast cancer
- Trial name
- NCT02883985
- Testing
- 6 Gy/ fraction
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- NYU Langone Health
Locally Advanced or Metastatic Solid Tumor
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in participants with advanced or metastatic…
- Trial name
- NCT03717415
- Testing
- Rebastinib, Carboplatin
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Neuropathic Pain, Chemotherapy Effect
Prevention of Paclitaxel-induced Neuropathic Pain in Patients With Planned Paclitaxel Chemotherapy (PrevTel)
Phase IIa clinical trial will be conducted with patients requiring in-label paclitaxel-chemotherapy due to ovarian or breast cancer.
- Trial name
- PrevTel (NCT05322889)
- Testing
- Telmisartan tablets
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Dr. Frank Behrens
Breast Neoplasms
Exercise in Women at Risk for Breast Cancer
This 2-part study will examine how much exercise people usually do in the course of their daily lives and how two different types of exercise-stretching and walking-affect the amount of fat in the body and certain hormones in the…
- Trial name
- NCT00092950
- Testing
- Physical activity
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Chronic Myeloproliferative Disorders
Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
RATIONALE: Antifungals such as ravuconazole may be effective in preventing fungal infections in patients undergoing chemotherapy and stem cell transplantation.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00064311
- Testing
- ravuconazole
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.